References
Lai SW (2018) Tamoxifen administration and risk of Parkinson’s disease. Eur J Clin Pharmacol. https://doi.org/10.1007/s00228-018-2553-y
Montastruc F, Khosrow-Khavar F, de Germay S, Renoux C, Rousseau V, Durrieu G, Montastruc M, Rascol O, Sommet A, Lapeyre-Mestre M, Benevent J, Montastruc JL (2018) Tamoxifen and the risk of parkinsonism: a case/non-case study. Eur J Clin Pharmacol 74:1181–1184
Latourelle JC, Dybdahl M, Destefano AL, Myers RH, Lash TL (2010) Risk of Parkinson's disease after tamoxifen treatment. BMC Neurol 10:23
Lin HF, Liao KF, Chang CM, Lin CL, Lai SW (2018) Tamoxifen usage correlates with increased risk of Parkinson's disease in older women with breast cancer: a case-control study in Taiwan. Eur J Clin Pharmacol 74:99–107
Hong CT, Chan L, Hu CJ, Lin CM, Hsu CY, Lin MC (2017) Tamoxifen and the risk of Parkinson’s disease in female patients with breast cancer in Asian people: a nationwide population-based study. J Breast Cancer 20:356–360
Faillie JL, Montastruc F, Montastruc JL, Pariente A (2016) Pharmacoepidemiology and its input to pharmacovigilance. Therapie 71:211–216
Faillie JL (2018) Case-non case studies: principles, methods, bias and interpretation. Therapie 73:247–255
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Montastruc, F., Khosrow-Khavar, F., Sommet, A. et al. Tamoxifen administration and the risk of Parkinsonism. Eur J Clin Pharmacol 75, 135–136 (2019). https://doi.org/10.1007/s00228-018-2554-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-018-2554-x